USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44CO120039
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
EUTROPICS PHARMACEUTICALS, INC.
60 GRAMPIAM WAY DORCHESTER, MA 02125-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA
Agency: HHS
Contract: N44CO120039
Award Amount: $1,499,746.00
 

Abstract:

There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve therapy efficacy for MM by using a proprietary assay that provides a novel predictive biomarker, BH3 profiling. The assay uniquely assesses mitochondrial functionality in cancer cells. This technology is proven in a patient testset to predict the patient responsiveness to standard treatments for MM. In this phase 2 contract Eutropics will establish and deliver a refined standard operating protocol for the BH3 profiling assay and a CLlA 88 approval. Biopsied MM patient samples continue to be obtained from several academic cancer centers and pharmaceutical companies under collaboration agreements. Further partnering with additional pharmaceutical companies will be established during this contract. A verification data set will be collected. From this the specificity and sensitivity of the assay and assay cutoffs will be established. A validation study in uniformly treated clinical trials patients will follow. Completion of this study will fulfill the contract.

Principal Investigator:

Michael Cardone
617-714-4405
MCARDONE@EUTROPICS.COM

Business Contact:

Michael Cardone
617-714-4405
MCARDONE@EUTROPICS.COM
Small Business Information at Submission:

EUTROPICS PHARMACEUTICALS, INC.
EUTROPICS PHARMACEUTICALS, INC. DORCHESTER, MA 99999-

EIN/Tax ID: 202971708
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No